Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 649 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema, Atopic Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 4, 2026, 4:49 AM EDT
Not yet recruiting No phase listed Observational

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

NCT06174493
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 4, 2026, 4:49 AM EDT
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

NCT03822832
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
BI 655130, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Not applicable Interventional

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

NCT01660217
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
A written Eczema Action Plan (EAP)
Other
Lead sponsor
Dermatology & Aesthetics of Wicker Park
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 4, 2026, 4:49 AM EDT
Recruiting No phase listed Observational

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed No phase listed Observational

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT05203380
View directory record Official record
Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Gilbert, Arizona • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 4, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT06397911
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB825, Placebo
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Fountain Valley, California • Fremont, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

NCT07242638
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata
Interventions
Abrocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

NCT05127421
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 4, 2026, 4:49 AM EDT
Recruiting Phase 3 Interventional

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

NCT06311682
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab + TCS, Placebo + TCS
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Months to 11 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Systems Biology of Early Atopy

NCT04798079
View directory record Official record
Conditions
Allergic Diseases, Food Allergy, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2032
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

NCT04823130
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab (SAR231893)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis

NCT00130364
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 11 Years
Enrollment
200 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Novartis Pharmaceuticals, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 4, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

NCT00703573
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 4, 2026, 4:49 AM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Not applicable Interventional

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis

NCT01675232
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Soak and smear, Dry Smear
Other
Lead sponsor
Yale University
Other
Eligibility
2 Weeks to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 4, 2026, 4:49 AM EDT
Active, not recruiting Not applicable Interventional

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

NCT07700745
View directory record Official record
Conditions
Eczema, Atopic Dermatitis, Eczema-Prone Skin
Interventions
Rejuvaskin Eczema Body Wash
Dietary Supplement
Lead sponsor
Rejuvaskin
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

NCT02087943
View directory record Official record
Conditions
Dermatitis, Atopic Dermatitis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 4, 2026, 4:49 AM EDT
Completed Phase 4 Interventional

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis

NCT00667160
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
19
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 4, 2026, 4:49 AM EDT